Pieris Pharmaceuticals (PIRS)
(Delayed Data from NSDQ)
$17.24 USD
+0.25 (1.47%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $17.50 +0.26 (1.51%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Pieris Pharmaceuticals, Inc. [PIRS]
Reports for Purchase
Showing records 41 - 60 ( 91 total )
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Can These Guys Partner or What? Third Deal in 13 Months Signed
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Spotlight on Two Lead Assets at First KOL Event
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Driving Toward an Important Boost in Anticalin Visibility This Year; Target Increased to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
PRS-060 Goes Clinical and Pieris Cashes a Check
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q17 Results; Moving Forward on Many Fronts; Clinical Data Should Start Rolling In
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Charting New Territory With First Anticalin Multi-Dose Study; Phase 2a Underway
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q17 Results; Building Activity Across Programs and Partnerships; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
PRS-080 Phase 1b Data in CKD Patients Highlights Potential of the Novel Anticalins; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
PRS-080 Phase 1b Data in CKD Patients Highlights Potential of the Novel Anticalins; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Anticalins for All; What Do You Want to Target? Initiating Coverage at Buy and $9 PT
Provider: Rodman & Renshaw, Co.
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Anticalins for All; What Do You Want to Target? Initiating Coverage at Buy and $9 PT
Provider: H.C. Wainwright & Co., Inc.
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Corrected - Coverage Update - Healthcare
Provider: Roth Capital Partners, Inc.
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are transferring coverage due to the departure of the covering analyst
Provider: Roth Capital Partners, Inc.
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Coverage Update - Healthcare
Provider: Roth Capital Partners, Inc.
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Cancer in Washington: 2017 AACR Highlights
Provider: Roth Capital Partners, Inc.
Analyst: BREIDENBACH M
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Cancer in Washington: 2017 AACR Highlights
Provider: Roth Capital Partners, Inc.
Analyst: BREIDENBACH M
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We are transferring coverage to Mark Breidenbach, Ph.D., due to the departure of the covering analyst and placing shares Under Review.
Provider: Roth Capital Partners, Inc.
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Innovations in Oncology Corporate Access Day Recap
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q16 Results; Busy Times at the Company as We Await Catalysts
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Pieris Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.